Skip to main content

Elizabeth Parsons


[email protected]



Elizabeth represents and counsels clients in connection with technology transactions and IP prosecution matters. She has a particular focus on the life sciences industry, as well as significant IP experience in renewable energy, software, financial services, e-commerce, telecommunications, manufacturing, and education.

Elizabeth’s experience includes:

  • Drafting and negotiating a wide variety of agreements, including licenses, joint development agreements, CRADAs, supply and manufacturing agreements, sponsored research agreements and settlement agreements
  • Conducting and managing IP due diligence for technology transactions, including M&A and licensing transactions
  • Drafting and prosecuting US and international patents related to technologies including drug delivery, antibodies, DNA probes, nanotechnology, semiconductor memory, image sensors, and photovoltaic modules
  • Providing patentability and infringement opinions
  • Providing counseling in connection with litigation and disputes related to technology, such as breaches of license, IP infringement and trade secret misappropriation

During law school, Elizabeth interned for the Honorable William Nickerson of the US District Court for the District of Maryland.

She is an accomplished equestrian and a former dressage instructor.


  • University of Maryland School of Law (JD, with honors)
  • University of Maryland (BS, Biochemistry)


  • Mintz represented Kimberly-Clark Corporation in selling its transdermal, micro-needle drug delivery division (Sofusa) to Sorrento Therapeutics for a total of $310M ($10M upfront + $300M in milestones and earn-outs). Mintz will represent the newly-formed Sorrento division going forward.
  • Mintz represented KeraNetics in its merger with Microchips Biotech, forming a new company known as Keratin Biosciences. The company, which will maintain locations in Winston-Salem, North Carolina, and Lexington, Massachusetts, will focus on effectively delivering keratin-based regenerative medicine developed by KeraNetics via Microchips’ proprietary microchip implant which stores and releases drug doses over extended periods.
  • Mintz represented the leadership of newly-formed Viela Bio in its spin-out from AstraZeneca’s MedImmune division. The spin-out included investment by AstraZeneca, 6 Dimensions Capital, Boyu Capital, Hillhouse Capitals, Temasek, and Sirona Capital. Viela Bio will build itself around three clinical and preclinical compounds targeting inflammatory and autoimmune diseases, including one which is in Phase II development.
  • Mintz represented Immucor, a leading worldwide provider of transfusion and transplantation diagnostic products, in acquiring a series of companies operating at the cutting-edge of the industry, quickly expanding the technical depth of the company and expanding its reach into new markets. LifeCodes (January 2013 – $85 million – from Hologic) Organ-i (June 2014 – value undisclosed) Sentilus (October 2014 – value undisclosed) Sirona Genomics (October 2014 collaboration agreement resulted in March 2016 acquisition)
  • Represent as outside IP counsel, a world leader in immunohematology and molecular diagnostics in in all aspects of intellectual property, including patent procurement and defense, licensing and other technology-related transactions.


  • Board member, Great and Small (a nonprofit therapeutic riding organization)
  • Board member, New York Artists Equity Association, Inc.

Recent Insights

News & Press

News & Press

This article focuses on the spin-off of biotech startup Viela Bio from AstraZeneca’s research and development arm MedImmune Inc. The coverage notes that Members Chris Jeffers and Elizabeth Parsons helped negotiate the deal along with AstraZeneca’s legal team. Chris and Elizabeth are quoted in the article discusses considerations that need to be made during spinouts such as this one.